Tech glitch­es over­shad­ow FDA on­col­o­gy ad­comm as a sol­id ma­jor­i­ty of ad­vis­ers vote to keep Roche's Tecen­triq in mTNBC

Kick­ing off three days of re­ex­am­in­ing an­ti-PD(L)-1 ac­cel­er­at­ed ap­provals, the FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee start­ed slow­ly on Tues­day. Af­ter a more than hour-long tech­ni­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.